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ABSTRACT
Purpose: Hormone resistance remains a significant clin-
ical problem in prostate cancer with few therapeutic options.
Research into mechanisms of hormone resistance is essen-
tial.
Experimental Design: We analyzed 38 paired (prehor-
mone/posthormone resistance) prostate cancer samples us-
ing the Vysis GenoSensor. Archival microdissected tumor
DNA was extracted, amplified, labeled, and hybridized to
Amplionc I DNA microarrays containing 57 oncogenes.
Results: Genetic instability increased during progres-
sion from hormone-sensitive to hormone-resistant cancer
(P  0.008). Amplification frequencies of 15 genes (TERC,
MYBL3, HRAS, PI3KCA, JUNB, LAMC2, RAF1, MYC,
GARP, SAS, FGFR1, PGY1, MYCL1, MYB, FGR) increased
by >10% during hormone escape. Receptor tyrosine kinases
were amplified in 73% of cases; this was unrelated to devel-
opment of hormone resistance. However, downstream re-
ceptor tyrosine kinase signaling pathways showed increased
amplification rates in resistant tumors for the mitogen-
activated protein kinase (FGR/Src-2, HRAS, and RAF1; P 
0.005) and phosphatidylinositol 3-kinase pathways (FGR/
Src-2, PI3K, and Akt; P  0.046). Transcription factors
regulated by these pathways were also more frequently
amplified after escape (MYC family: 21% before versus 63%
after, P 0.027; MYB family: 26% before versus 53% after,
P  0.18).
Conclusions: Development of clinical hormone escape is
linked to phosphatidylinositol 3-kinase and mitogen-acti-
vated protein kinase pathways. These pathways may func-
tion independently of the androgen receptor or via androgen
receptor activation by phosphorylation, providing novel
therapeutic targets.
INTRODUCTION
Treatment of advanced prostate cancer has relied on an-
drogen deprivation therapy for the past 50 years. Response rates
are initially high (70–80%), however, almost all patients expe-
rience treatment failure (hormone escape), with a median time to
relapse of 18 months (1). Their cancer then progresses, fre-
quently with metastasis and increased risk of morbidity and
death (2). Unlike breast cancer, alternative approaches (chem-
otherapy and radiotherapy) do not provide significant disease
control after the development of hormone escaped. The high rate
of prostate cancer mortality is, therefore, linked strongly to both
development of hormone escape and the lack of alternate ther-
apies.
The lack of progress in developing novel therapies to treat
hormone escape is linked closely to a lack of understanding of
the molecular mechanisms underlying the development of this
disease. Understanding why this occurs will also enable us to
use therapies that are currently available for treatment of other
solid tumor types.
To date, the majority of research on hormone escape has
focused on the AR2; however, mutations and amplifications of
the AR are not found frequently enough to alone explain the
development of hormone escape (3–7). Furthermore, we have
recently demonstrated a significant amplification of the AR
before antiandrogen therapy in a patient who had a full clinical
response to antiandrogens, including a reduction in PSA (8).
Hormone escape may, therefore, develop because of alternative
methods of regulating AR protein activation rather than modi-
fications to the receptor itself.
Phosphorylation of the AR seems to play a role in both
ligand-dependent and ligand-independent AR activation (9–13).
Therefore, although it seems that activation of the AR is central
to the development of hormone escape, it may be because of
activation of the AR in an androgen-independent manner by
alternative pathways.
Cell line studies have demonstrated that various pathways
[PI3K/Akt (14, 15), Ras/MAPK (16, 17), protein kinase A (18),
and protein kinase C (19)] may have a role in the development
of hormone escape; however, the significance of these pathways
in the clinical setting has not been investigated. This study has
used two matched tumors from each patient with prostate can-
cer, one tumor before and one tumor after the development of
hormone escape. Analysis of tumor DNA using CGH arrays will
allow us to identify gene abnormalities in tumors after the
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development of hormone escape that are not present in the
matched tumor that responded to androgen deprivation therapy.
Although this CGH array method does not generally differenti-
ate between amplification and gain in copy number, the results
obtained for individual genes within a chromosomal region
can aid differentiation between amplification and gain in copy
number.
MATERIALS AND METHODS
Patients. Nineteen patients (38 matched tumor pairs)
were retrospectively selected for analysis; all tumors had patient
identification removed, including block number and hospital
number, and were coded to make the database anonymous.
Ethical approval was obtained from the Multicenter Research
Ethics Committee for Scotland and the appropriate local re-
search and ethical committees for use of matched hormone-
sensitive and hormone-resistant tumors in our study. All patients
received conventional androgen deprivation therapy (orchidec-
tomy, antiandrogens, or androgen ablation therapy). Patients
were selected for analysis if they initially responded to treatment
(response was defined by PSA levels falling by at least 50%) but
subsequently relapsed. PSA values and full clinical follow-up
was available for each patient (Table 1). Patients were classed as
having hormone-escaped cancer when sustained rising PSA
levels were noted and were selected for study if a posthormone
relapse sample was available. The initial tumor sample was
either a TURP or a transrectal ultrasound-guided biopsy, how-
ever, the relapsed tumor sample was always a TURP, which was
performed to treat clinical symptoms, most commonly bladder
outflow obstruction.
DNA. Archival (formalin fixed, paraffin embedded)
prostate tumors and normal colorectal tissue (normal control)
were microdissected from 5-m sections, as described by Going
and Lamb (20). DOP-PCR was performed according to the
method of Speicher et al. (21) to amplify all DNA [DNA
extracted from prostate and colorectal tissue, DNA (positive
control; Vysis Inc., Downers Grove, IL), and normal reference
male DNA]. The concentration of PCR products was determined
by spectrophotometry.
Nick Translation. DOP-PCR product (1.5 g) from ei-
ther reference (male DNA) or test (male DNA extracted from
colon tissue, COSH DNA, or tumor DNA) samples were nick
translated using the Vysis Nick translation kit in a final volume
of 50 l. Reference DNA were labeled with Alexa 594 dUTP
(red), and test DNA with Alexa 488 dUTP (green). Samples
were incubated at 37°C for 30 min, followed by enzyme dena-
turation at 80°C for 10 min. Samples were chilled, and 2 l of
precipitation reagent, 5 l of 3 M sodium acetate, and 55 l of
isopropanol were added to precipitate DNA. Samples were
placed at 20°C for at least 1 h, and DNA was pelted at
15,000  g for 15 min at room temperature. The supernatant
was removed, and pellets were washed in 300 l of 70%
ethanol, spun, and resuspended in 7.5 l of nuclease-free water
(200 ng/l). After labeling, 0.5 g of each product was run on
a 2% agarose gel to confirm the success of the reaction.
Hybridization. Test DNA (2.5 l, 0.5 g) and 2.5 l of
reference DNA were combined with 22 l of hybridization
buffer (total volume, 27 l). Samples were heated to 80°C for
10 min and allowed to cool to 37°C. Samples were then prehy-
bridized for 2–6 h before placing on Genosensor Amplionc I
microarrays. Microarrays were then incubated for 18 h at 37°C.
Table 2 shows a list of the genes and location of genes on the
array.
Posthybridization Washes. Arrays were washed in
wash solution (50% formamide and 2 SSC) three times at
40°C for 10 min. This was followed by four washes for 5 min
in 1 SSC at room temperature. After air drying, 4,6-
diamidino-2-phenylindole IV was applied to counterstain the
DNA. After 15 min, arrays were imaged using the Genosensor
and the Genosensor Reader Software.
Table 1 Patient information
Patient no. Age (yr) Primary surgery
Information at
diagnosis
Relapse surgery
Information at
relapse
Time to relapse
(days) TreatmentGleason score PSA Gleason score PSA
1 71 TURP 5 39 TURP 6 8 1553 Finesteride
2 72 TURP 6 64 TURP 9 39 1097 Orch, zoladex
3 74 TURP 4 1 TURP 10 29 893 Orch, zoladex
4 54 TURP 7 10 TURP 8 59 2087 Orch, flutamide
5 71 TURP 9 152 TURP 9 116 693 Orch, zoladex, casodex
6 66 TURP 10 306 TURP 10 44 850 Orch, flutamide
7 62 Tru-cut biopsy 9 207 TURP 8 31 1046 Zoladex, casodex
8 83 Tru-cut biopsy 10 42 TURP 8 7 765 Zoladex, flutamide
9 67 Tru-cut biopsy 8 55 TURP 9 7 3031 Zoladex
10 71 Tru-cut biopsy 8 112 TURP 8 16 714 Zoladex, casodex
11 76 Tru-cut biopsy 8 1300 TURP 8 796 686 Zoladex
12 68 TURP 9 10 TURP 9 3 966 Zoladex
13 76 TURP 7 136 TURP 9 140 1410 Zoladex
14 69 Tru-cut biopsy 6 7 TURP 10 15 616 Zoladex, casodex
15 64 TURP 8 384 TURP 7 36 356 Zoladex
16 70 TURP 6 6 TURP 9 17 60 Zoladex
17 73 TURP 9 208 TURP 7 52 1224 Orch
18 63 TURP 7 24 TURP 9 33 1593 Orch
19 81 TURP 7 2 TURP 8 3 1821 Orch
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Normal DNA Controls. Reference DNA arrays versus
COSH DNA (DNA with known amplifications and losses)
arrays were initially performed to confirm that DOP-PCR was
not biasing the results, therefore validating the technique. There-
after, one reference DNA array versus COSH DNA array was
performed per run as a positive control. Reference DNA arrays
versus normal male DNA (extracted from colorectal archival
tissue) arrays were performed on 10 occasions to establish the
normal range when using archival DNA amplified by DOP-
PCR. The mean hybridization ratio  2 SD (red:green fluores-
cence ratio) was calculated using the Genosensor software.
Statistics. The total number of amplifications before and
after hormone escape were analyzed using Wilcoxon’s signed
ranks test. The number of amplifications per gene or signaling
pathway were analyzed using McNemar’s test.
RESULTS
The mean test:normal ratio for the CGH array was calcu-
lated for 10 arrays (1770 spots) using DOP-PCR-amplified
DNA extracted from archival colorectal tissue. The mean hy-
bridization ratio and SD for each individual gene across the 10
arrays is shown in Table 2. The mean hybridization ratio for all
genes across the 10 arrays was 0.944  0.217 (mean  SD).
The range of normal values for hybridization, as defined by
these control experiments, was 0.727–1.161. We defined the
95% confidence interval of the mean hybridization signal
(0.944  2 SD) as the normal range for hybridization ratios.
Thus, the normal range for hybridization ratios was 0.510–
1.378; values 0.510 identify loss (“deletion”), and values
1.378 identify gain (“amplification”).
Amplifications Associated with Prostate Cancer. In
total, 287 of 2142 (13.4%) spots from the 38 tumor samples
showed ratios above 1.378 and were, therefore, scored as am-
plified. Fewer (18 of 2142, 0.8%) spots showed clear loss (ratios
0.5). Amplifications ranged from 2 to 14 genes/tumor with a
median of 7 (interquartile range, 6–10). Deletions ranged from
zero to four genes/tumor with a median of 0 (interquartile range,
0–1). Overall, tumors showed alterations (amplifications and
deletions) in 2–17 genes with a median of 7 (interquartile range,
6–11). No alterations were observed in 13 genes; an additional
29 genes were altered in 15% of cases, and 16 genes were
altered in 15% of cases. The 16 most commonly altered genes
are shown in Fig. 1, this graph shows the copy number for each
gene in each individual tumor and the average copy number 
SD for the colon controls (Fig. 1). The AR copy number was
most frequently out of the normal range; because AR is the only
gene on the array that is on the X chromosome, AR results in
this study measure AR copy number, not amplification. The AR
copy number was confirmed by FISH; 65% of tumors had an
abnormal copy number by the array method compared with 61%
by FISH, and there was a 92% correlation between the methods
(Table 3). Eighteen percent of the tumors were found to be
amplified for the AR using FISH (Table 3).
When oncogenes associated with signal transduction path-
ways were investigated, it was noted that 22% of tumors were
amplified for members of the type I RTK family (EGFR, 11%;
Table 2 Gene array targets
Gene Location Average SD Gene Location Average SD
FGR 1p36.2-p36.1 0.95 0.03 WNT1 12q12-q13 0.75 0.14
MYCL1 1p34.3 1.15 0.29 GLI 12q13.2-q13.3 0.80 0.10
NRAS 1p13.2 1.00 0.23 SAS/CDK4 12q13.3 0.96 0.17
LAMC2 1q25-q31 0.89 0.12 MDM2 12q14.3-q15 0.81 0.22
MYCN 2p24.1 0.80 0.10 Akt1 14q32.3 0.75 0.23
REL 2p13-p12 0.76 0.13 IGFR1 15q25-q26 0.87 0.26
RAF1 3p25 1.14 0.06 FES 15q26.1 0.69 0.12
TERC 3q26.3 1.12 0.03 MRP1 16p13.1 1.02 0.08
P13K 3q26.3 1.14 0.05 TOP2A 17q21-q22 0.86 0.17
PDGFRA 4q12 0.87 0.23 HER2 17q21.2 0.95 0.21
MYB 6q22 1.06 0.17 RPS6KB1 17q23 0.96 0.09
ESR 6q25.1 1.18 0.19 D17S1670 17q23 0.98 0.16
EGFR 7p12.3-p12.1 0.89 0.11 YES1 18p11.3 1.02 0.09
PGY1 7q21.1 0.99 0.15 BCL2 3 18q21.3 1.06 0.12
MET 7q31 0.88 0.06 BCL2 5 18q21.3 1.03 0.14
CTSB 8p22 0.99 0.31 INSR 19p13.2 1.10 0.06
FGFR1 8p11.2-p11.1 0.94 0.21 JUNB 19p13.2 0.56 0.07
MOS 8q11 0.97 0.09 CCNE1 19q13.1 0.92 0.16
MYC 8q24.12-q24.13 0.89 0.17 AIB1 20q12 1.05 0.21
ABL1 9q34.1 0.88 0.20 STK15 20q13 0.98 0.08
FGFR2 10q26 1.18 0.07 CSE1L 20q13 1.00 0.15
HRAS 11p15.5 1.03 0.20 MYBL2 20q13.1 0.87 0.16
CCND1 11q13 0.98 0.13 PTPN1 20q13.1-q13.2 0.82 0.09
FGF4/FGF3 11q13 0.80 0.20 ZNF217 20q13.2 0.93 0.19
EMS1 11q13 1.02 0.24 CBFA2 21q22.3 1.01 0.20
GARP 11q13.5-q14 1.08 0.21 BCR 22q11.21 0.93 0.15
PAK1 11q13.5-q14 1.01 0.10 PDGFB 22q12.3-q13.1 0.74 0.17
MLL 11q23 0.91 0.16 AR 5 Xq11-q12 0.86 0.15
CCND2 12p13 0.90 0.25 AR 3 Xq11-q12 1.22 0.21
KRAS2 12p12.1 0.90 0.15
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HER2, 11%). Nineteen percent of cases were amplified for
members of the type II RTK family of receptors (INSR, 6%;
IGF1 receptor, 13%), 11% were amplified for type III RTKs/
ligands (PDGFRA, 8%; PDGFB/c-sis, 3%), and 47% for type
IV RTKs (FGFR1, 9%; FGFR2, 47%; Fig. 2). In total, 73% of
prostate cancer cases showed amplification of classical growth
factor cell surface RTKs or their ligands. Only 18% of cases
were amplified for more than one type of RTK. There was no
evidence for nonrandom association of amplification.
In addition to amplification of cell surface receptors and
their ligands, frequent amplification of members of the MAPK
cascade were observed (FGR/Src-2, 18%; NRAS, 48%; HRAS,
11%; KRAS, 14%; RAF1, 11%). When all cases were taken into
consideration, 74% (28 of 38) of tumors showed amplification
for key elements of the MAPK cascade. It was also observed
that 44% (16 of 36) of cases were amplified for PI3K. When the
above data were combined, 87% (33 of 38) of prostate tumors
showed amplification of RTK genes or genes downstream of
these (i.e., FGR/RAS/RAF1/PI3K; Fig. 3). Only five cases
(13.2%) showed no detectable amplification of these pathways.
When transcription factors regulated by the RTK signal
transduction pathways were investigated, 40% (15 of 38) of
tumors were amplified for members of the MYB family (MYB,
29%; MYBL2, 16%) and 47% of tumors were amplified for the
MYC family (MYCL1, 35%; MYCN, 14%; MYC, 8%; Fig. 2).
Amplifications Associated with Hormone Escape. Sig-
nificantly fewer genes were amplified in hormone-sensitive
tumors when compared with hormone-escaped tumors (11.7%
versus 15.2%; P  0.008). Seventeen genes were amplified in
15% of hormone-sensitive tumors, and 24 genes were ampli-
fied in 15% of hormone-escaped tumors (Table 4). AR (63%
prehormone and 67% posthormone; only gene on X chromo-
some), FGFR2 (50% prehormone and 44% posthormone; only
gene on chromosome 10), PI3K (39% prehormone and 50%
posthormone), and NRAS (47% prehormone and 47% posthor-
mone) all demonstrated copy number gains in 35% of both
hormone-sensitive and hormone-escaped tumors (Table 4).
Forty-six percent (27 of 59) of genes investigated were
amplified and increased copies relative to adjacent genes on the
same chromosome more frequently in hormone-escaped tumors
compared with hormone-sensitive tumors. An increase of10%
in the frequency of amplification or gain during transition from
hormone-sensitive to hormone-escaped prostate cancer was ob-
served for 15 genes (Fig. 4). FGR (Src-2; control MYCL1) was
amplified in significantly more hormone-escaped tumors (37%,
7 of 19) compared with hormone-sensitive tumors (0%, 0 of 19;
P  0.016).
When RTK oncogenes were compared in hormone-sensi-
tive and hormone-escaped prostate cancer, there was no signif-
icant difference in the amplification rate when compared as
families (type I RTK: 5 of 19 versus 3 of 19, P  0.69; type II
RTK: 3 of 19 versus 4 of 19, P  0.41; type III RTK: 2 of 19
versus 2 of 19, P 1; type IV RTK: 9 of 19 versus 9 of 19, P
0.1) or when combined (15 of 19 versus 13 of 19, P 0.71). An
increase was, however, observed for FGFR1 (control MOS; 0 of
18 versus 3 of 17, P  0.25).
A significant increase was seen in the frequency of ampli-
fications for members of the MAPK cascade [FGR (Src-2),
HRAS, and RAF1] with the development of hormone escape
[10% (2 of 19) versus 58% (11 of 19), P  0.005; Table 5]. In
Fig. 1 The copy number of each gene for each tumor is indicated by a square, and the average copy number for each gene calculated from the normal
colon controls is indicated by a circle. The error bars on the circles denote the SD, and the horizontal lines on the graph at 0.378 and 0.51 are the
cutoffs used in this study to determine the normal range.
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47% (9 of 19) of cases, either FGR (Src-2) or HRAS was
amplified during hormone escape, and in only 1 case (5%) were
they both amplified; an additional 2 cases (11%) showed am-
plification of RAF1 at hormone escape (Table 5).
It was observed that 39% of hormone-sensitive tumors and
50% of hormone-escaped tumors were amplified for PI3K (Ta-
ble 5). No tumors were observed to be amplified for Akt1.
Coamplification of PI3K and FGR (Src-2) was observed in 0%
(0 of 19) of hormone-sensitive tumors and 26% (5 of 19) of
hormone-escaped tumors (P  0.046; Table 4).
Transcription factors (MYC and MYB) regulated by the
MAPK or PI3K cascade were amplified more frequently in
hormone-escaped tumors (MYC and MYCL1: 21% prehormone
versus 63% posthormone, P  0.02; MYB and MYBL2: 26%
prehormone versus 53% posthormone, P  0.18; Table 5).
Amplifications for FGR (Src-2)/HRAS/RAF1/MYC/MYCL1
were observed in 32% (6 of 19) of hormone-sensitive cases and
74% (14 of 19) of hormone-escaped cases (P  0.02). Ampli-
fications for FGR (Src-2) and PI3K/MYBL2/MYB were observed
in 26% (5 of 19) of hormone-sensitive cases and 53% (10 of 19)
of hormone-escaped cases (P  0.18). Amplification rates in-
crease for either the MAPK or PI3K pathways in 79% (15 of 19)
of cases with the development of hormone escape, and 58% (11
of 19) of these were gains in a novel pathway.
DISCUSSION
The development of hormone resistance in prostate cancer
is among the most significant causes of morbidity and mortality
from this disease. The object of this study was to identify
molecular aberrations that occur at the development of hor-
mone-escaped prostate cancer using matched tumors before and
after hormone escape. Using a targeted CGH microarray ap-
proach, we were able to identify individual genes that are
commonly amplified in prostate cancer and those likely to be
involved in the development of hormone escape. A series of
gene amplifications associated with the development of hor-
mone escape were identified linking cell surface receptors,
through signal transduction pathways, to nuclear transcription
factors.
The most frequent regions of amplification detected were
within the 1p amplicon, frequently associated with prostate
cancer in conventional CGH studies (22, 23), with amplification
of FGR (1p36; Refs. 22 and 23), MYCL1 (1p34.3; Ref. 22), and
NRAS (1p13.2) occurring in over 60% of cases. In addition,
frequent amplification of LAMC2 (1q25; Refs. 24 and 25) was
observed. Within the 1p amplicon, however, there appeared to
be little evidence of linkage between gene alterations, but this
region is commonly reported as gained by CGH (22, 23). Other
hot spots for amplification were similar to those reported in the
literature as detected by CGH in prostate cancer, including PI3K
(3q26.3; Refs. 23, 25, and 26), PGY1 (7q21.1; Refs. 23 and 27),
STK15 (20q13; Ref. 23), and AR (Xq12; Refs. 22–24 and 28). In
the case of PI3K, PGY1, and STK15, genes found in similar loci
(TERC, 3q26.3), MET (7q21), and CSE1L (20q13), respectively,
were infrequently coamplified, suggesting these genes are spe-
cific targets within these regions. In each case, however, ex-
pression analysis will be required for final confirmation that
these are indeed the target genes within these frequently ampli-
fied regions. The presence of multiple, but apparently independ-
ent, alterations within the 1p amplicon reflects similar data we,
and others, have observed in genomic mappings studies. AR was
the most frequently modified gene (Table 3), with the copy
number being increased in 65% of cases, which is within the
range reported in the literature for AR copy number (35–80%;
Refs. 5, 7, and 8). AR copy number rates correlate (92%) with
the results we found using FISH for AR and X chromosome
copy number in the same patient cohort. This figure is higher
than the AR amplification rate reported in the literature (20–
30%; Refs. 29 and 30), because it measures AR copy number,
not amplification; however, using FISH, the level of amplifica-
tion in this cohort was 18%, which is similar to that reported in
the literature (5–8). We have noted that, although there exists a
strong correlation between gene copy number detected by FISH
and that detected on microarrays, a doubling of gene copy
detected by FISH does not equate to a doubling of the hybrid-
ization ratio seen on microarrays. This can be demonstrated
clearly by the observation that ratios above 1.378 on the mi-
croarray are indicative of abnormal gene copy numbers whereas
Table 3 Correlation between FISH gene array results
Case no. Tumor no.
Abnormal
copy number
by array
Abnormal
copy number
by FISH
Amplified
by FISH
1 1  
2 No result 
2 3  
4  
3 5   
6   
4 7
8  
5 9
10 No result
6 11
12  
7 13
14
8 15 
16
9 17  
18 No result
10 19
20
11 21 
22  
12 23
24
13 25  
26  
14 27  
28 No result  
15 29
30  
16 31  
32  
17 33  
34  
18 35  
36  
19 37  
38  
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a significantly higher figure (1.5–2.0) is required to identify
abnormal gene copy numbers by FISH (29, 30).
The molecular mechanisms underlying the development of
hormone resistance in prostate cancer is still poorly understood.
Within this study, we have the unique opportunity to compare
molecular alterations within tumors collected before and after
hormone relapse, where each patient’s pretreatment tumor acts
as a linked control. We have used this approach previously to
confirm that AR amplification cannot always explain hormone
escape and in some cases may be present in hormone-sensitive
tumors (8). Data from the current study further emphasizes this
by confirming our finding that AR gene copy does not increase
with hormone escape. We, therefore, looked for other genetic
patterns associated with hormone resistance. Our results identify
growth factor pathways, which may play a role in the develop-
ment of hormone resistance.
We show that type I–IV RTKs are amplified in 	73% of
prostate cancers (Fig. 2). Frequency of amplifications were low
for type I–III RTKs (type I, 22%; type II, 19%; type III, 11%),
however, 47% of cases were amplified for type IV RTKs
(FGFR1 and FGFR2). There was no significant difference be-
tween amplification frequencies in the transition from hormone-
sensitive to hormone-insensitive prostate cancer, but a trend was
observed with the FGFR1 amplification rate increasing from 0%
to 17.65%. Many studies have investigated the role of type I
RTKs in hormone-escaped prostate cancer. Here, we report that
11% of tumors are amplified for EGFR. This value is marginally
higher than that reported in the literature (3–9%; Ref. 29),
however, it is still within the general range. This figure could be
higher because higher-grade tumors are used or because of
duplication of the short arm of chromosome 7, because the other
genes present on the chip are found on the long arm of chro-
mosome 7. Duplication of the short arm would not be noted by
amplification of other genes on the chip, therefore, there is no
internal control of this gene. Although EGFR amplification
might result in an increase in EGFR expression, which has been
reported previously to predict prostate cancer progression, it has
been reported that the mutated form of EGFR, which is consti-
tutively active (EGFRvIII), is frequently overexpressed in pros-
tate cancer (30, 31). This study also reported that 11% of tumors
were amplified for HER2, also within the range (0–44%) re-
ported in the literature [e.g., Mark et al. (32) reported 9.3%, and
Ross et al. (33) reported 41% ]. Overexpression of p185HER2 is
associated with poor prognosis (31, 32, 34), and we have dem-
onstrated by FISH that HER2 amplification rates increase with
grade in prostate tumors.3
The FGFs and their receptors are involved in the develop-
ment of the fetal prostate gland and have been reported to be
involved in prostate cancer (35). FGFR2 is expressed in normal
prostate epithelium and, with its ligand KGF/FGF-7 (androgen-
inducible paracrine factor), is involved in regulating the devel-
opment and growth of the normal prostate (36). Although
FGFR2 mutations or polymorphisms are not commonly found
in prostate cancer, increased mRNA expression has been de-
tected (36) that could be a consequence of FGFR2 gains seen in
this study (no control gene is on the array to allow differentia-
tion between amplification or gain of FGFR2; Fig. 1). We noted
that during the transition to hormone resistance the rate of
3 J. Edwards, personal communication.
Fig. 2 The total percentage of
tumors amplified for cell sur-
face RTK are shown in Fig. 1.
Each family [type I (EGFR
and HER2), type II (INSR and
IGF1), type III (PDGFB and
PDGFRA), and type IV
(FGFR1 and FGFR2)] is shown
for each individual family
member and the family in total.
5276 Gene Amplifications in Hormone Relapsed Prostate Cancer
FGFR1 amplification of increases (Table 4), suggesting that this
receptor may be important in the development of hormone
escape. In the Dunning rat model, FGFR1 expression can induce
hormone escape concurrent with loss of FGFR2 (37). Although
this study observes amplification of FGFR1 with the develop-
ment of hormone escape, this was not significant; the role of this
receptor, therefore, seems to be minor in this cohort. Because
there is no significant change in the cell surface RTK amplifi-
cation rate with the development of hormone escape, we have to
conclude from these data that RTK amplification is not in-
volved. We are, however, currently studying protein expression
and activation status of RTKs to determine whether, in prostate
cancer, protein expression is not amplification driven.
RTKs are responsible for the regulation of downstream
signaling pathways, including the RAS/RAF/MAPK and PI3K/
Akt pathways. These pathways control cell proliferation, differ-
entiation, and apoptosis (Refs. 15 and 38; Fig. 3) and have been
implicated previously in the development of hormone escape in
prostate cancer cell lines (14, 38).
Alterations to HRAS, NRAS, and KRAS, the three human
RAS genes (39, 40), are associated with many advanced human
cancers (e.g., lung, thyroid, breast, bladdern and ovarian tumors;
Ref. 41). They are amplified frequently in this study, and for
HRAS an increase in amplification rates is associated with
hormone resistance (Table 4). These oncogenes function via the
activation of MAPK, although many of the upstream compo-
nents of the MAPK cascade are activated via a series of phos-
phorylation events, activated MAPK relays signals to the nu-
cleus via other kinases, and nuclear transcription factors
including fos, myc, and jun (41). In addition, a significant
increase in the frequency of Src-2 (FGR) amplifications was
seen at hormone escape (Table 4; P  0.016). In only one case
were HRAS and Src-2 both amplified; therefore, in 47% of
cases, either Src-2 or HRAS was gained during the process of
hormone escape. Furthermore, HRAS or Src-2 were amplified
infrequently (5%) before hormone escape (Table 5). RAS am-
plifications are often a consequence of RAS mutations that result
in activated Ras protein (42) and may, therefore, be considered
an indicator of activated Ras. Furthermore, mutated Ras has
been associated previously with chemoresistance in breast can-
cer. Srcs are activated by binding to SH2 domains of RTKs (43)
but also interact with Ras in activating the Raf/MAPK pathway
(44–47), which has been associated with hormone escape in
prostate cancer cell lines. MAPK has been shown to stimulate
prostate cancer cell growth in the absence of androgens via
phosphorylation (serine 515) and activation of the AR (48).
Therefore, amplification and, presumably, activation of one or
the other partner in this interaction could act to stimulate sig-
naling via RAF1 and the MAPK cascade, activating AR-respon-
sive genes and facilitating hormone resistance. In almost 60% of
cancers, we have shown evidence for modification of the Src-
2/HRAS/RAF1 cascade during hormone escape. This study has,
therefore, identified a key molecular mechanism responsible for
the development of hormone escape, because the MAPK path-
way is activated by a range of growth factors and growth factor
receptors and results in the activation of many nuclear transcrip-
tion factors.
RTKs also activate the PI3K/Akt pathway (Refs. 48 and
49; Fig. 3), predominantly to regulate apoptosis. This pathway
has been reported to be involved with many human cancers
Fig. 3 Interactions between the Src-2/RAS/RAF/MAPK and Src-2/PI3K/Akt pathways and related transcription factors in the hormone-resistant
prostate cancer cell. Activation of both these pathways may result in phosphorylation and, hence, activation of the AR in the absence of androgens.
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[e.g., breast and ovarian (50)]. Here, we report that PI3K am-
plification rates increase from 39% to 50% with the develop-
ment of hormone resistance; however, Akt was not amplified in
any of the tumors we analyzed. The PI3K/Akt pathway has been
implicated in hormone-resistant prostate cancer (14, 48, 49)
because activated Akt modifies and stimulates AR in the ab-
sence of androgens via phosphorylation of serine 213 (14). Akt
activation status is controlled by the PTEN phosphatase, with
inactivating mutations of PTEN leading to activation of Akt
(48–53). PTEN, a protein phosphatase that is one of the most
widely mutated tumor suppressor genes in prostate cancer, is
mutated in 29–42% of prostate cancers and in up to 60% of
prostate cancer cell lines (50). Src-2 directly inhibits the action
of PTEN, leading to activation of Akt via PI3K (54). Therefore,
Srcs in addition to modifying the RAS/MAPK pathway, may act
synergistically with PI3K amplifications to modify Akt (43) and
thereby modify apoptotic control in prostate cancers. Activation
of Akt may cause Bcl-2 and Bcl-XL proteins to function as
inhibitors of apoptosis. Akt phosphorylates a proapoptotic mem-
ber of the Bcl-2 family that, when dephosphorylated, displaces
Bax from Bcl-2 and Bcl-XL complexes, ultimately resulting in
cell death (51). Overexpression of Bcl-2 has been implicated
previously in the conversion of androgen-dependent to an-
drogen-independent disease (50), and expression of Bcl-2 in
LNCaP cells protects cells from apoptosis caused by androgen
withdrawal and enables cells to grow in the absence of andro-
gens (51). Therefore, there is strong evidence that increased
activation of the PI3K/Akt pathway could induce hormone
resistance via an increase in Bcl-2 expression. The development
of hormone resistance in this patient group was associated with
gain of coamplification of Src-2 and PI3K (26%; Table 5).
Therefore, we hypothesize that PTEN inactivation, because of
Src-2 amplification, combined with amplification of PI3K re-
sults in increased Akt activity and activation of the AR and/or
Bcl-2, leading to the development of hormone escape.
The Src-2/HRAS and the Src-2/PI3K pathway effects are
mediated by different classes of transcription factors (MYC, jun,
and fos and MYB, Bad, and caspase 9, respectively; Refs. 55
and 56). Amplification rates of MYC (MYC, MYCL1) and MYB
(MYB, MYBL2) transcription increased significantly during de-
velopment of hormone escape. Amplification of MYC has been
reported previously in clinical samples to increase with the
development of hormone escape (23, 26, 57) and in presence of
distant metastases (7). Protein expression of c-myc also in-
creases after androgen deprivation (58) and binds to a myc
consensus site on the AR coding region (59). Binding of c-myc
to the AR coding region results in an increase in AR mRNA
expression and AR protein levels (58). Akt is the principal
transducer of the MYB family of transcription factors, which are
highly regulated throughout the cell cycle and are required for
cell cycle progression (21, 56). Overexpression of the MYB
family has been demonstrated to protect cells from programmed
cell death and also to regulate cell adhesion (21, 56). Combining
amplification of these transcription factors with their respective
Table 4 Gene amplifications detected by array CGH
Gene
Hormone-sensitive tumors Hormone-escaped tumors
PAmplifications Tumors Percentage Amplifications Tumors Percentage
MET 3 16 18.75 0 19 0.00 0.250
PTPN1 2 18 11.11 0 18 0.00 0.500
KRAS2 4 19 21.05 1 18 5.56 0.375
HER2 3 19 15.79 1 18 5.56 1.000
MYCN 3 18 16.67 2 18 11.11 1.000
D17S1670 1 19 5.26 2 18 11.11 1.000
CBFA2 3 18 16.67 3 19 15.79 1.000
IGFR1 2 19 10.53 3 19 15.79 1.000
TERC 1 18 5.56 3 19 15.79 0.500
HRAS 1 19 5.26 3 19 15.79 0.500
MYC 0 18 0.00 3 19 15.79 0.250
CSE1L 2 15 13.33 3 18 16.67 0.500
JUNB 1 18 5.56 3 18 16.67 0.500
RAF1 1 19 5.26 3 18 16.67 0.500
FGFR1 0 18 0.00 3 17 17.65 0.250
MYBL2 2 19 10.53 4 19 21.05 0.625
GARP 1 17 5.88 4 18 22.22 0.250
CTSB 5 17 29.41 6 19 31.58 1.000
ESR 4 18 22.22 6 19 31.58 0.625
STK15 5 18 27.78 6 18 33.33 1.000
SAS/CDK4 3 18 16.67 6 18 33.33 0.250
FGR(Src-2) 0 19 0.00 7 19 36.84 0.016
LAMC2 5 18 27.78 7 18 38.89 0.500
PGY1 3 15 20.00 7 18 38.89 0.375
MYB 3 19 15.79 8 19 42.11 0.063
FGFR2 9 18 50.00 8 18 44.44 1.000
NRAS 9 19 47.37 9 19 47.37 1.000
MYCL1 4 18 22.22 9 19 47.37 0.125
PI3K 7 18 38.89 9 18 50.00 0.375
AR 12 19 63.16 10 15 67.23 1.000
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upstream regulators (Table 5) demonstrated that 73% of cases
were amplified for HRAS/RAF1/Src-2/MYC/MYCL1 after hor-
mone escape versus 31% before hormone escape. Overall, 53%
of cases were amplified for Src-2 and PI3K and/or MYB/MYBL2
after hormone relapse versus 26% before hormone relapse. In
58% of cases, this represented an amplification in a novel
pathway arising during the development of hormone escape.
We, therefore, conclude from the data presented here that am-
plification of key genes within the RAS/MAPK and PI3K path-
ways are involved in the development of hormone escape in the
majority of prostate cancers. Both of these pathways are increas-
ingly implicated the development of prostate cancer and are also
implicated with developing resistance in an increasing number
of other cancers, most notably breast cancer, which is also a
hormonally regulated disease (41, 50).
We also reported increased genetic instability as a tumor
progresses, from hormone-sensitive to hormone-escaped pros-
tate cancer (P 0.008), with amplification of multiple members
of the PI3K pathway and the MAPK cascade being more com-
monly observed in hormone-escaped prostate cancer. Amplifi-
cation rates of other genes, however, also increased with the
development of hormone escape (CDK4 and PYG1; Fig. 4).
CDK4 belongs to the ser/thr family of protein kinases and is
involved in the control of the cell cycle (60). PGY1 is the gene
for human multidrug resistance protein 1 (61). This protein
functions as an energy-dependent efflux pump and is responsi-
ble for decreasing drug accumulation in cells (61). Expression of
MDR1 is associated with poor response to chemotherapy in
breast carcinoma, therefore, it is not surprising that overex-
Fig. 4 Percentage of tumors amplified for each individual gene in both the hormone-sensitive (white) and hormone-escaped (gray) tumors. Only
genes with an amplification rate increased by 10% in the transition from hormone sensitive to hormone escape are shown. The FGR (Src-2)
amplification rate significantly increased with the development of hormone escape (P  0.016, McNemar’s test).
Table 5 Signal transduction pathway genes
Hormone sensitive Hormone escaped P
MAPK pathway
FGR(Src-2)(control MYCL2) 0% (0/19) 37% (7/19) 0.016
HRAS (control FGF3) 5% (1/19) 16% (3/19) 0.500
RAF1 (control TERC) 5% (1/19) 17% (3/18) 0.500
MYC/MYCL1 (control MOSF/FGR) 21% (4/19) 63% (12/19) 0.027
FGR/HRAS/RAF1 10% (2/19) 60% (11/19) 0.005
FGR/HRAS/RAF1MYC/MYCL1 31% (6/19) 74% (14/19) 0.024
P13K pathway
FGR(Src-2) (control MYCL2) 0% (0/19) 37% (7/19) 0.016
PI3K (control TERC) 39% (7/18) 50% (9/18) 0.375
FGR(Src-2) and PI3K 0% (0/19) 26% (5/19) 0.046
Akt (no control) 0% (0/19) 0% (0/19) 1.000
MYB/MYB12 (control ERS/CSE1L) 26% (5/19) 53% (10/19) 0.180
FGR(Src-2) and PI3K/MYB/MYB12 26% (5/19) 53% (10/19) 0.180
5279Clinical Cancer Research
pression of this protein might cause resistance to antiandrogen
therapies in prostate cancer (61). These may represent alterna-
tive pathways for hormone escape.
We have provided strong evidence that amplification or
gain of key genes within the RAS/MAPK and PI3K pathways,
including downstream transcription factors, drive the develop-
ment of hormone resistance in prostate cancers. These pathways
are not necessarily mutually exclusive, and multiple mecha-
nisms may arise in different groups of hormone-escaped pros-
tate cancer. Many drugs that target these pathways by inhibiting
specific members at the RTK level or down stream are currently
under development [e.g., Ras/Sulindac, RAF1/Bay439006, and
PI3K/wortmannin (62)]. We believe that additional research
might identify key modulators of hormone escape within these
pathways and will enable us to profile treatment for individual
tumors based on expression of these key genes.
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